Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stre… (NCT06672952) | Clinical Trial Compass
RecruitingNot Applicable
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
United States60 participantsStarted 2025-04-15
Plain-language summary
The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants who are between 18 - 50 years of age
✓. Body mass index values will range from \>25.0 \< 30.0 kg/m2
✓. The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg/m2
✓. Free-living and independent
✓. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders
✓. Willingness to maintain consistent sleep duration the evening before study visits
✓. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures
✓. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months
Exclusion criteria
✕. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months
✕. Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease
✕. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals
What they're measuring
1
Change from Baseline in Peak VO2 at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Timeframe: Baseline and Week 8
2
Change from Baseline in Wingate Anaerobic Test Peak Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Timeframe: Baseline and Week 8
3
Change from Baseline in Wingate Anaerobic Test Mean Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Timeframe: Baseline and Week 8
4
Change from Baseline in Fatigue Rate at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Timeframe: Baseline and Week 8
5
Change from Baseline in Perceived Indicators of Recovery, Training Readiness, Soreness, and Overall Feel Using Visual Analog Scales (VAS) at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Timeframe: Baseline and Week 8
6
Change from Baseline in Brachial Artery Blood Flow Measured 0, 30, and 60 Minutes After Acute and Prolonged Ingestion of Glucosyl-Hesperidin (CITRAPEAK)
Timeframe: Baseline and Week 8, measured at 0, 30, and 60 minutes post-ingestion.